Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition

AbstractPurpose of ReviewTo distinguish extreme and very high atherosclerotic cardiovascular disease (ASCVD) event risk based on prospective epidemiological studies and clinical trial results.Recent FindingsClinical practice guidelines have categorized patients with either a history of one or more “clinical ASCVD” events or “coronary heart disease (CHD) risk equivalency” to be at “very high risk” for a recurrence or a first event, respectively. A 20% or greater 10-year ASCVD risk for a composite 3-point “major” atherosclerotic cardiovascular event (MACE) of non-fatal myocardia l infarction (MI), non-fatal stroke, or cardiovascular death can serve as an arbitrary definition of those at “very high risk.” Exclusion of stroke may underestimate risk of “hard” endpoint 10-year ASCVD risk and addition of other potential endpoints, e.g., hospital admission for unstable an gina or revascularization, a 5-point composite MACE, may overinflate the risk definitions and categorization. “Extreme” risk, a descriptor for even higher morbidity and mortality potential, defines a 30% or greater 10-year 3-point MACE (ASCVD) risk. In prospective, epidemiological studies and ra ndomized clinical trial (RCT) participants with an initial acute coronary syndrome (ACS) within several months of entry into the study meet the inclusion criteria assignment for extreme risk. In survivors beyond the first year of an ASCVD eve...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research

Related Links:

Chronic cannabis use seemed to protect against in-hospital death and shorten length of stay in the observational study with propensity matching — but not in all types of heart failure.Medscape Medical News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Cardiology News Source Type: news
' There's once again excitement about renal artery denervation and … it's justified,'says one cardiologist, while another hopes for FDA approval next year, and a third is'still not 100% convinced. 'theheart.org on Medscape
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Cardiology Article Source Type: news
Conditions:   Pulmonary Arterial Hypertension;   Right-Sided Heart Failure Intervention:   Other: PET/MRI Sponsors:   University of Wisconsin, Madison;   United Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Type 2 Diabetes Intervention:   Diagnostic Test: Continuous glucose monitoring Sponsors:   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;   AztraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pregnancy;   Gestational Diabetes Intervention:   Behavioral: TLC Group Prenatal Care Sponsor:   Washington University School of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diabetes Mellitus, Type 2 Intervention:   Device: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle Sponsor:   Becton, Dickinson and Company Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion Activation of the Nrf2-dependent antioxidant system plays an important role in cell defense against oxidative stress damage, whereas the insufficiency of the Nrf2 system is associated with multiple aspects of the genesis and progression of metabolic diseases, posing a great risk to the cardiovascular system (Figure 1). The systemic increase of Nrf2 activity by several activators may be beneficial in the treatment of metabolic diseases. In addition, selective upregulation of Nrf2 genes may represent a potential therapy in obesity, diabetes and atherosclerosis. Looking to the future, experimental research that el...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In conclusion, senescence of vascular cells promotes the development of age-related disorders, including heart failure, diabetes, and atherosclerotic diseases, while suppression of vascular cell senescence ameliorates phenotypic features of aging in various models. Recent findings have indicated that specific depletion of senescent cells reverses age-related changes. Although the biological networks contributing to maintenance of homeostasis are extremely complex, it seems reasonable to explore senolytic agents that can act on specific cellular components or tissues. Several clinical trials of senolytic agents are currentl...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusions: Emerging economies are currently providing a base of cost evidence for NCD treatment that may prove useful to policy-makers in low-income countries. Initial steps to publicly finance disease interventions should take account of costs. The gaps and limitations in the current literature include a lack of standardized reporting as well as sparse evidence from low-income countries.
Source: BMC Public Health - Category: Consumer Health News Authors: Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Endocrinology | Epidemiology | Genetics | Heart | Heart Disease | Heart Failure | Hospitals | Hypertension | Ischemic Stroke | Stroke | Study | Urology & Nephrology